An open label multi facilities cooperation randomized control trial to verify urinary angiotensinogen excretion reducing effect of olmesartan therapy in diabetic nephropathy.

Trial Profile

An open label multi facilities cooperation randomized control trial to verify urinary angiotensinogen excretion reducing effect of olmesartan therapy in diabetic nephropathy.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2015

At a glance

  • Drugs Nifedipine (Primary) ; Olmesartan medoxomil (Primary)
  • Indications Diabetic nephropathies; Hypertension
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms ORION-Angel
  • Most Recent Events

    • 08 Jun 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 09 Mar 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top